NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-11-11
DOI
10.1002/jcb.29560
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
- (2018) Lei Zhang et al. NEURO-ONCOLOGY
- Circulating visfatin levels and cancers risk: A systematic review and meta-analysis
- (2018) Masoumeh Mohammadi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma
- (2018) J. Almeida et al. METABOLIC BRAIN DISEASE
- SERPINE1 IDENTIFIED AS POTENTIAL THERAPEUTIC TARGET THROUGH RNA-SEQ OF CLINICALLY RELEVANT INVASIVE GLIOBLASTOMA CELLS ISOLATED FROM PATIENTS BY 5-ALA BASED METHODOLOGY
- (2018) Jonathan Rowlinson et al. NEURO-ONCOLOGY
- Epidemiology and Overview of Gliomas
- (2018) Mary Elizabeth Davis Seminars in Oncology Nursing
- Progranulin and its biological effects in cancer
- (2017) Fabian Arechavaleta-Velasco et al. MEDICAL ONCOLOGY
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis
- (2017) Antonio Lucena-Cacace et al. Oncotarget
- Secret talk between adipose tissue and central nervous system via secreted factors—an emerging frontier in the neurodegenerative research
- (2016) Avinash Parimisetty et al. Journal of Neuroinflammation
- Role of interleukin-6 in cancer progression and therapeutic resistance
- (2016) Neeraj Kumari et al. TUMOR BIOLOGY
- Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2
- (2015) Tingting Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Obesity, adipokines and cancer: an update
- (2014) C.H. Lee et al. CLINICAL ENDOCRINOLOGY
- Adiponectin as Novel Regulator of Cell Proliferation in Human Glioblastoma
- (2014) Carola Porcile et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Adipokines – removing road blocks to obesity and diabetes therapy
- (2014) Matthias Blüher Molecular Metabolism
- Glioblastoma and Other Malignant Gliomas
- (2013) Antonio Omuro JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adipocytokines in relation to cardiovascular disease
- (2013) Johan Van de Voorde et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The Definition of Primary and Secondary Glioblastoma
- (2012) H. Ohgaki et al. CLINICAL CANCER RESEARCH
- Progranulin overexpression predicts overall survival in patients with glioblastoma
- (2011) Minqing Wang et al. MEDICAL ONCOLOGY
- Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders
- (2011) Stefan Lehr et al. Proteomics Clinical Applications
- PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value
- (2010) P. Sreekanth Reddy et al. CANCER BIOLOGY & THERAPY
- High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas
- (2009) Carole Colin et al. ACTA NEUROPATHOLOGICA
- Adipose Tissue Dysfunction in Obesity
- (2009) M. Blüher EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Heterogeneous activation of the TGFβ pathway in glioblastomas identified by gene expression-based classification using TGFβ-responsive genes
- (2009) Xie L Xu et al. Journal of Translational Medicine
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started